CoChat

Avelumab in Combination with Axitinib as First-Line Treatment in Patients with Advanced Hepatocellular Carcinoma: Results from the Phase 1b VEGF Liver 100 Trial

Open access
Kudo, Masatoshi, Motomura, Kenta, Wada, Yoshiyuki, Inaba, Yoshitaka, Sakamoto, Yasunari, Kurosaki, Masayuki, Umeyama, Yoshiko, Kamei, Yoichi, Yoshimitsu, Junichiro, Fujii, Yosuke, Aizawa, Mana, Robbins, Paul B., Furuse, Junji · 2021 · Liver Cancer
Cited by 101

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

Introduction: Combining an immune checkpoint inhibitor with a targeted antiangiogenic agent may leverage complementary mechanisms of action for the treatment of advanced/metastatic hepatocellular carcinoma (aHCC). Avelumab is a human anti-PD-L1 IgG1 antibody with clinical activity in various tumor types; axitinib is a selective tyrosine kinase inhibitor of vascular endothelial growth factor receptors 1, 2, and 3. We report the final analysis from VEGF Liver 100 (NCT03289533), a phase 1b study evaluating safety and efficacy of avelumab plus axitinib in treatment-naive patients with aHCC. Methods: Eligible patients had confirmed aHCC, no prior systemic therapy, ≥1 measurable lesion, Eastern Cooperative Oncology Group performance status ≤1, and Child-Pugh class A disease. Patients received avelumab 10 mg/kg intravenously every 2 weeks plus axitinib 5 mg orally twice daily until progression, unacceptable toxicity, or withdrawal. Endpoints included safety and investigator-assessed objective response per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 and modified RECIST (mRECIST) for HCC. Results: Twenty-two Japanese patients were enrolled and treated with avelumab plus axitinib. The minimum follow-up was 18 months as of October 25, 2019 (data cutoff). Grade 3 treatment-related adverse events (TRAEs) occurred in 16 patients (72.7%); the most common (≥3 patients) were hypertension (n = 11 [50.0%]), palmar-plantar erythrodysesthesia syndrome (n = 5 [22.7%]), and decreased appetite (n = 3 [13.6%]). No grade 4 TRAEs or treatment-related deaths occurred. Ten patients (45.5%) had an immune-related AE (irAE) of any grade; 3 patients (13.6%) had an infusion-related reaction (IRR) of any grade, and no grade ≥3 irAE and IRR were observed. The objective response rate was 13.6% (95% CI: 2.9–34.9%) per RECIST 1.1 and 31.8% (95% CI: 13.9–54.9%) per mRECIST for HCC. Conclusion: Treatment with avelumab plus axitinib was associated with a manageable toxicity profile and showed antitumor activity in patients with aHCC.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1159/000514420

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 21

  1. 10.3322/caac.21492 · DOI · Paper page
  2. 10.1038/s41575-019-0186-y · DOI · Paper page
  3. 10.1056/NEJMoa0708857 · DOI · Paper page
  4. 10.1016/S0140-6736(18)30207-1 · DOI · Paper page
  5. 10.1111/cei.12069 · DOI · Paper page
  6. 10.1056/NEJMoa1915745 · DOI · Paper page
  7. 10.1016/S1470-2045(17)30239-5 · DOI · Paper page
  8. 10.1158/2326-6066.CIR-15-0059 · DOI · Paper page
  9. 10.1016/S1470-2045(17)30240-1 · DOI · Paper page
  10. 10.1186/s40425-019-0746-2 · DOI
  11. 10.1016/j.ejca.2011.07.014 · DOI
  12. 10.1093/jjco/hyt054 · DOI
  13. 10.1111/cas.12546 · DOI
  14. 10.1111/cas.13232 · doi:10.1111/cas.13232
  15. 10.1093/jjco/hyw103 · doi:10.1093/jjco/hyw103
  16. 10.1093/annonc/mdv388 · DOI
  17. 10.1159/000484620 · DOI
  18. 10.1056/NEJMoa1816047 · DOI · Paper page
  19. 10.1111/cas.14294 · DOI
  20. 10.1055/s-0030-1247132 · DOI · Paper page
  21. 10.1200/JCO.20.00808 · DOI · Paper page

Cited by

See all 101

Metadata

Authors
Kudo, M., Motomura, K., Wada, Y., Inaba, Y., Sakamoto, Y., Kurosaki, M., Umeyama, Y., Kamei, Y., Yoshimitsu, J., Fujii, Y., Aizawa, M., Robbins, P. B., & Furuse, J.
Venue
Liver Cancer
Publisher
S. Karger AG
Published
2021
Volume
10
Issue
3
Pages
249-259
ISSN
  • 1664-5553 (ISSN-L)
  • 2235-1795
OpenAlex
W3145648199
Cited by
101
References
8
FWCI
8.08
Type
journal article
Language
en
Open access
gold
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.